Predictive AI Biomarker for Lung Cancer Immunotherapy by Lunit Inc. to augment growth of Companion diagnostics and cancer biomarker market

On May 28 Lunit Inc. announced an abstract presentation of its AI precision medicine research portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2019. The accepted abstract highlights the feasibility of AI-based biomarker in metastatic non-small cell lung cancer, based on the H&E analysis that predicts response to immune checkpoint inhibitors (ICI).